A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

NCT01168973 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1253

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: Ramucirumab
DRUG: Placebo (for Ramucirumab)
DRUG: Docetaxel

Sponsor

Eli Lilly and Company